Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro

Catechins may influence both desirable and undesirable effects of many drugs. In this study, the in vitro effect of (+)-catechin, (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate, and (-)-epigallocatechin gallate (EGCG) on the efficacy of anticancer drug doxorubicin (DOX) was studied i...

Full description

Saved in:
Bibliographic Details
Main Authors: Rudolfová Petra, Hanušová Veronika, Skálová Lenka, Bártíková Hana, Matoušková Petra, Boušová Iva
Format: Article
Language:English
Published: Sciendo 2014-06-01
Series:Acta Pharmaceutica
Subjects:
Online Access:http://www.degruyter.com/view/j/acph.2014.64.issue-2/acph-2014-0018/acph-2014-0018.xml?format=INT
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Catechins may influence both desirable and undesirable effects of many drugs. In this study, the in vitro effect of (+)-catechin, (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate, and (-)-epigallocatechin gallate (EGCG) on the efficacy of anticancer drug doxorubicin (DOX) was studied in HCT-8 cancer cells. Rat hepatocytes were used to study the influence of EGCG on DOX hepatotoxicity. Cell proliferation and viability were studied by 3-[4,5-dimethylthiazol- 2-yl]-2,5-diphenyl tetrazolium bromide and neutral red uptake test assays. Formation of reactive oxygen species (ROS) was determined using the dichlorofluorescein assay. All of the studied catechins (1-25 μmol L-1) had no effect on the proliferation of intestinal cancer cells and did not affect the antiproliferative effect of DOX (1-8 μmol L-1) in these cells. Moreover, EGCG at 25 μmol L-1 increased the viability of isolated hepatocytes and significantly protected these cells against DOX-induced toxicity and ROS production. Consumption of EGCG during DOX therapy seems to be safe and beneficial, since EGCG does not decrease DOX anticancer efficacy and could ameliorate DOX hepatotoxicity
ISSN:1330-0075
1846-9558